<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37450244</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>The Molecular Link Between TDP-43, Endogenous Retroviruses and Inflammatory Neurodegeneration in Amyotrophic Lateral Sclerosis: a Potential Target for Triumeq, an Antiretroviral Therapy.</ArticleTitle><Pagination><StartPage>6330</StartPage><EndPage>6345</EndPage><MedlinePgn>6330-6345</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-023-03472-y</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurological disorder, characterised by the death of upper and lower motor neurons. The aetiology of ALS remains unknown, and treatment options are limited. Endogenous retroviruses (ERVs), specifically human endogenous retrovirus type K (HERV-K), have been proposed to be involved in the propagation of neurodegeneration in ALS. ERVs are genomic remnants of ancient viral infection events, with most being inactive and not retaining the capacity to encode a fully infectious virus. However, some ERVs retain the ability to be activated and transcribed, and ERV transcripts have been found to be elevated within the brain tissue of MND patients. A hallmark of ALS pathology is altered localisation of the transactive response (TAR) DNA binding protein 43&#xa0;kDa (TDP-43), which is normally found within the nucleus of neuronal and glial cells and is involved in RNA regulation. In ALS, TDP-43 aggregates within the cytoplasm and facilitates neurodegeneration. The involvement of ERVs in ALS pathology is thought to occur through TDP-43 and neuroinflammatory mediators. In this review, the proposed involvement of TDP-43, HERV-K and immune regulators on the onset and progression of ALS will be discussed. Furthermore, the evidence supporting a therapy based on targeting ERVs in ALS will be reviewed.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubowsky</LastName><ForeName>Megan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0146-4814</Identifier><AffiliationInfo><Affiliation>College of Medicine and Public Health and Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia. megan.dubowsky@flinders.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theunissen</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Jillian M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health and Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Mary-Louise</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health and Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1950</GrantID><Agency>Motor Neurone Disease Australia</Agency><Country/></Grant><Grant><GrantID>1950</GrantID><Agency>Andrew Butcher Grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020077" MajorTopicYN="Y">Endogenous Retroviruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Antiretroviral therapy</Keyword><Keyword MajorTopicYN="N">Endogenous retrovirus</Keyword><Keyword MajorTopicYN="N">HERV-K neuroinflammation</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">Triumeq</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37450244</ArticleId><ArticleId IdType="pmc">PMC10533598</ArticleId><ArticleId IdType="doi">10.1007/s12035-023-03472-y</ArticleId><ArticleId IdType="pii">10.1007/s12035-023-03472-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Traynor BJ. Motor neuron disease in 2014: biomarkers for ALS&#x2013;in search of the promised land. Nat Rev Neurol. 2015;11(2):72. doi: 10.1038/nrneurol.2014.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.250</ArticleId><ArticleId IdType="pmc">PMC5185468</ArticleId><ArticleId IdType="pubmed">25534912</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster LA, Salajegheh MK (2018) Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med</Citation><ArticleIdList><ArticleId IdType="pubmed">30075105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC. Motor neuron disease in 2017: progress towards therapy in motor neuron disease. Nat Rev Neurol. 2018;14(2):65. doi: 10.1038/nrneurol.2017.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.186</ArticleId><ArticleId IdType="pubmed">29348545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Bonetto V, Pupillo E, Logroscino G, Al-Chalabi A, Lunetta C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2020;21(7&#x2013;8):485&#x2013;495. doi: 10.1080/21678421.2020.1779298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779298</ArticleId><ArticleId IdType="pubmed">32583689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Van Den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227&#x2013;240. doi: 10.2353/ajpath.2007.070182.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070182</ArticleId><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol: Official Journal of the American Neurological Association and the Child Neurology Society. 2007;61(5):427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyburn L, Moussa CEH. TDP-43 in the spectrum of MND-FTLD pathologies. Mol Cell Neurosci. 2017;83:46&#x2013;54. doi: 10.1016/j.mcn.2017.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2017.07.001</ArticleId><ArticleId IdType="pmc">PMC5581706</ArticleId><ArticleId IdType="pubmed">28687523</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem. 2018;146(1):7&#x2013;20. doi: 10.1111/jnc.14327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, Perez-Berlanga M, Polymenidou M. Structural transition, function and dysfunction of TDP-43 in neurodegenerative diseases. CHIMIA Int J Chem. 2019;73(5):380&#x2013;390. doi: 10.2533/chimia.2019.380.</Citation><ArticleIdList><ArticleId IdType="doi">10.2533/chimia.2019.380</ArticleId><ArticleId IdType="pubmed">31118120</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, Chi&#xf3; A, Savelieff MG, Kiernan MC, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):465&#x2013;479. doi: 10.1016/S1474-4422(21)00414-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol. 2020;11:279. doi: 10.3389/fneur.2020.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00279</ArticleId><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin X-Y, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Pandya D, Pasternack N, Garcia-Montojo M, Henderson L, Kozak CA, et al. Retroviral elements in pathophysiology and as therapeutic targets for amyotrophic lateral sclerosis. Neurotherapeutics. 2022;19(4):1085&#x2013;1101. doi: 10.1007/s13311-022-01233-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01233-8</ArticleId><ArticleId IdType="pmc">PMC9587200</ArticleId><ArticleId IdType="pubmed">35415778</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, Doucet-O&#x2019;Hare T, Henderson L, Nath A. Human endogenous retrovirus-K (HML-2): a comprehensive review. Crit Rev Microbiol. 2018;44(6):715&#x2013;38. doi: 10.1080/1040841X.2018.1501345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1040841X.2018.1501345</ArticleId><ArticleId IdType="pmc">PMC6342650</ArticleId><ArticleId IdType="pubmed">30318978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes JF, Coffin JM. Human endogenous retrovirus K solo-LTR formation and insertional polymorphisms: implications for human and viral evolution. Proc Natl Acad Sci. 2004;101(6):1668&#x2013;1672. doi: 10.1073/pnas.0307885100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307885100</ArticleId><ArticleId IdType="pmc">PMC341815</ArticleId><ArticleId IdType="pubmed">14757818</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69(1):141&#x2013;151. doi: 10.1002/ana.22149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22149</ArticleId><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner JP, Bachani M, Malik N, DeMarino C, Li W, Sampson K, et al. Human endogenous retrovirus K envelope in spinal fluid of amyotrophic lateral sclerosis is toxic. Ann Neurol. 2022;92(4):545&#x2013;561. doi: 10.1002/ana.26452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26452</ArticleId><ArticleId IdType="pmc">PMC9489628</ArticleId><ArticleId IdType="pubmed">35801347</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;nsson ME, Garza R, Sharma Y, Petri R, S&#xf6;dersten E, Johansson JG, et al. Activation of endogenous retroviruses during brain development causes an inflammatory response. EMBO J. 2021;40(9):e106423. doi: 10.15252/embj.2020106423.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106423</ArticleId><ArticleId IdType="pmc">PMC8090857</ArticleId><ArticleId IdType="pubmed">33644903</ArticleId></ArticleIdList></Reference><Reference><Citation>Manghera M, Ferguson-Parry J, Lin R, Douville RN. NF-&#x3ba;B and IRF1 induce endogenous retrovirus K expression via interferon-stimulated response elements in its 5&#x2032; long terminal repeat. J Virol. 2016;90(20):9338&#x2013;9349. doi: 10.1128/JVI.01503-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01503-16</ArticleId><ArticleId IdType="pmc">PMC5044829</ArticleId><ArticleId IdType="pubmed">27512062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1):1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76(11):1367&#x2013;1374. doi: 10.1001/jamaneurol.2019.2044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie Ian R, Boeve Bradley F, Boxer Adam L, Baker M, Rutherford Nicola J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Bosco D, Leclerc A, Tamrazian E, Vanderburg C, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34(6):404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Lee VM, Trojanowski JQ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011;17(11):659&#x2013;667. doi: 10.1016/j.molmed.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.06.004</ArticleId><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Hirano A, Kobayashi M, Siddique T, Deng H-X, Hung W-Y, et al. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J Neuropathol Exp Neurol. 1996;55(4):481&#x2013;490. doi: 10.1097/00005072-199604000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199604000-00011</ArticleId><ArticleId IdType="pubmed">8786408</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A, Nutini M, Longone P (2019) Glutamate in amyotrophic lateral sclerosis: an ageless contestant. Pathology, prevention and therapeutics of neurodegenerative disease: Springer. p. 61&#x2013;71</Citation></Reference><Reference><Citation>Ruegsegger C, Saxena S. Proteostasis impairment in ALS. Brain Res. 2016;1648:571&#x2013;579. doi: 10.1016/j.brainres.2016.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.03.032</ArticleId><ArticleId IdType="pubmed">27033833</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Morfini GA. Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol Dis. 2017;105:273&#x2013;282. doi: 10.1016/j.nbd.2017.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.04.010</ArticleId><ArticleId IdType="pmc">PMC5522763</ArticleId><ArticleId IdType="pubmed">28411118</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley J, Clarke BE, Patani R. The interplay of RNA binding proteins, oxidative stress and mitochondrial dysfunction in ALS. Antioxidants. 2021;10(4):552. doi: 10.3390/antiox10040552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10040552</ArticleId><ArticleId IdType="pmc">PMC8066094</ArticleId><ArticleId IdType="pubmed">33918215</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x11f;atay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep. 2018;8(1):7083. doi: 10.1038/s41598-018-25008-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25008-4</ArticleId><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator ofCFTR exon 9. J Biol Chem. 2001;276(39):36337&#x2013;36343. doi: 10.1074/jbc.M104236200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein a/b through its c-terminal tail an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280(45):37572&#x2013;37584. doi: 10.1074/jbc.M505557200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505557200</ArticleId><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VMY, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13:38. doi: 10.1038/nrn3121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi PP ed (2017) Transcription and splicing factor TDP-43: role in regulation of gene expression in testis. Semin Reprod Med; Thieme Medical Publishers</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9208725</ArticleId><ArticleId IdType="pubmed">28278534</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SS, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81(3):536&#x2013;543. doi: 10.1016/j.neuron.2013.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111(4):1051&#x2013;1061. doi: 10.1111/j.1471-4159.2009.06383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06383.x</ArticleId><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garc&#xed;a-Mart&#xed;nez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69(6):3584. doi: 10.1128/jvi.69.6.3584-3596.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.6.3584-3596.1995</ArticleId><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya KK, Govind CK, Shore AN, Stoler MH, Reddi PP. cis-Requirement for the maintenance of round spermatid-specific transcription. Dev Biol. 2006;295(2):781&#x2013;90. doi: 10.1016/j.ydbio.2006.04.443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2006.04.443</ArticleId><ArticleId IdType="pubmed">16730344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalmansingh AS, Urekar CJ, Reddi PP. TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo. J Biol Chem. 2011;286(13):10970&#x2013;82. doi: 10.1074/jbc.M110.166587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.166587</ArticleId><ArticleId IdType="pmc">PMC3064152</ArticleId><ArticleId IdType="pubmed">21252238</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, D&#xf6;rk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20(7):1774&#x2013;1784. doi: 10.1093/emboj/20.7.1774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose JK, Wang I-F, Hung L, Tarn W-Y, Shen C-KJ. TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing&#x2217;. J Biol Chem. 2008;283(43):28852&#x2013;9. doi: 10.1074/jbc.M805376200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805376200</ArticleId><ArticleId IdType="pmc">PMC2661999</ArticleId><ArticleId IdType="pubmed">18703504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Mol Biol Cell. 2009;20(12):2864&#x2013;2873. doi: 10.1091/mbc.e09-02-0168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e09-02-0168</ArticleId><ArticleId IdType="pmc">PMC2695794</ArticleId><ArticleId IdType="pubmed">19386761</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452&#x2013;458. doi: 10.1038/nn.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Rademakers R, Petrucelli L. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimers Dis. 2013;33(s1):S35&#x2013;S45. doi: 10.3233/JAD-2012-129036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-129036</ArticleId><ArticleId IdType="pmc">PMC3532959</ArticleId><ArticleId IdType="pubmed">22751173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M, Lee S, Jeon Y-M, Kim S, Kwon Y, Kim H-J. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020;52(10):1652&#x2013;1662. doi: 10.1038/s12276-020-00513-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00513-7</ArticleId><ArticleId IdType="pmc">PMC8080625</ArticleId><ArticleId IdType="pubmed">33051572</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol. 2011;18(7):822. doi: 10.1038/nsmb.2053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2053</ArticleId><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen H-J, Shaw CE. TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics. 2015;12(2):352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avenda&#xf1;o-V&#xe1;zquez SE, Dhir A, Romano M, D'Ambrogio A, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277&#x2013;288. doi: 10.1038/emboj.2010.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CC, Jin LW, Wang IF, Wei WY, Ho PC, Liu YC, et al. HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies. EMBO Mol Med. 2020;12(6):e10622. doi: 10.15252/emmm.201910622.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201910622</ArticleId><ArticleId IdType="pmc">PMC7278561</ArticleId><ArticleId IdType="pubmed">32449313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci. 2019;116(10):4696&#x2013;4705. doi: 10.1073/pnas.1818415116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. 2019;27(5):1409&#x2013;21.e6. doi: 10.1016/j.celrep.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley JR, Kirby J, Jansweijer JA, Webb PS, Hewamadduma CA, Heath PR, et al. Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones. Neuropathol Appl Neurobiol. 2014;40(6):670&#x2013;685. doi: 10.1111/nan.12148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12148</ArticleId><ArticleId IdType="pubmed">24750229</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjork RT, Mortimore NP, Loganathan S, Zarnescu DC. Dysregulation of translation in TDP-43 proteinopathies: deficits in the rna supply chain and local protein production. Front Neurosci. 2022;16:840357. doi: 10.3389/fnins.2022.840357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.840357</ArticleId><ArticleId IdType="pmc">PMC8935057</ArticleId><ArticleId IdType="pubmed">35321094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Yan T, Perry G, Wang X. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Mol Cell Neurosci. 2019;100:103396. doi: 10.1016/j.mcn.2019.103396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2019.103396</ArticleId><ArticleId IdType="pmc">PMC6874890</ArticleId><ArticleId IdType="pubmed">31445085</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan RK, Mangelsdorf M, Panwar A, Butler TJ, Noakes PG, Wallace RH. Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2013;14(4):252&#x2013;260. doi: 10.3109/21678421.2012.734520.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.734520</ArticleId><ArticleId IdType="pubmed">23134510</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, Priesmann D, Gradus-Pery T, Farberov L, et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12(1):1&#x2013;17. doi: 10.1038/s41467-021-27221-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27221-8</ArticleId><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y-F, Gendron TF, Zhang Y-J, Lin W-L, Alton S, Sheng H, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30(32):10851. doi: 10.1523/JNEUROSCI.1630-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22(8):869&#x2013;878. doi: 10.1038/nm.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Capitini C, Fani G, Dobson CM, Cecchi C, Chiti F. Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) proteinopathies. J Biol Chem. 2016;291(37):19437&#x2013;19448. doi: 10.1074/jbc.M116.737726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.737726</ArticleId><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Curr Opin Neurol. 2021;34(5):765&#x2013;772. doi: 10.1097/WCO.0000000000000983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000983</ArticleId><ArticleId IdType="pubmed">34402459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75(6):681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnick ND, Griffey CJ, Guarnieri P, Gerbino V, Wang X, Piersaint JA, et al. Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS. Proc Natl Acad Sci. 2017;114(39):E8294&#x2013;E8303. doi: 10.1073/pnas.1704294114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1704294114</ArticleId><ArticleId IdType="pmc">PMC5625902</ArticleId><ArticleId IdType="pubmed">28904095</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang J-Y, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8(347):347ra93&#x2013;ra93. doi: 10.1126/scitranslmed.aaf6038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Levin SC, Willis EF, Li R, Woodruff TM, Noakes PG. Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2018;15(1):171. doi: 10.1186/s12974-018-1217-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1217-2</ArticleId><ArticleId IdType="pmc">PMC5984816</ArticleId><ArticleId IdType="pubmed">29859100</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci. 2019;116(6):2312&#x2013;2317. doi: 10.1073/pnas.1815961116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Cleveland DW. Tuning apoptosis and neuroinflammation: TBK1 restrains RIPK1. Cell. 2018;174(6):1339&#x2013;1341. doi: 10.1016/j.cell.2018.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.08.035</ArticleId><ArticleId IdType="pubmed">30193106</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Huo Y, Bai J, Wang H, Wang H, Yang F, et al. Inflammatory cytokine levels in patients with sporadic amyotrophic lateral sclerosis. Neurodegener Dis. 2021;21(3&#x2013;4):87&#x2013;92. doi: 10.1159/000522078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000522078</ArticleId><ArticleId IdType="pubmed">35124669</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103&#x2013;1116. doi: 10.1002/acn3.51078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90(12):1338&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Karnaros V, Benyamin B, Schultz DW, Dubowsky M, Wuu J, et al. Urinary neopterin: a novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(4):990&#x2013;999. doi: 10.1111/ene.15237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15237</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-H, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183(3):636&#x2013;649.e18. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer AL, Abdullah A, Taylor JM, Crack PJ. The complexity of the cGAS-STING pathway in CNS pathologies. Front Neurosci. 2021;15:621501. doi: 10.3389/fnins.2021.621501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.621501</ArticleId><ArticleId IdType="pmc">PMC7900568</ArticleId><ArticleId IdType="pubmed">33633536</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu C, Li X, Li P. The mechanism of double-stranded DNA sensing through the cGAS-STING pathway. Cytokine Growth Factor Rev. 2014;25(6):641&#x2013;648. doi: 10.1016/j.cytogfr.2014.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.06.006</ArticleId><ArticleId IdType="pmc">PMC4254336</ArticleId><ArticleId IdType="pubmed">25007740</ArticleId></ArticleIdList></Reference><Reference><Citation>Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS&#x2013;STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548&#x2013;569. doi: 10.1038/s41577-021-00524-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00524-z</ArticleId><ArticleId IdType="pmc">PMC8029610</ArticleId><ArticleId IdType="pubmed">33833439</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JM, Moore Z, Minter MR, Crack PJ. Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer&#x2019;s disease. J Neural Transm. 2018;125(5):797&#x2013;807. doi: 10.1007/s00702-017-1745-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1745-4</ArticleId><ArticleId IdType="pubmed">28676934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofer MJ, Campbell IL. Type I interferon in neurological disease&#x2014;the devil from within. Cytokine Growth Factor Rev. 2013;24(3):257&#x2013;267. doi: 10.1016/j.cytogfr.2013.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2013.03.006</ArticleId><ArticleId IdType="pubmed">23548179</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul BD, Snyder SH, Bohr VA. Signaling by cGAS&#x2013;STING in neurodegeneration, neuroinflammation, and aging. Trends Neurosci. 2021;44(2):83&#x2013;96. doi: 10.1016/j.tins.2020.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.008</ArticleId><ArticleId IdType="pmc">PMC8662531</ArticleId><ArticleId IdType="pubmed">33187730</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O&#x2019;Rourke JG, Y&#xe1;&#xf1;ez A, Markman JL, Ho R, Wang X, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585(7823):96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazmi A, Field RH, Griffin EW, Haugh O, Hennessy E, Cox D, et al. Chronic neurodegeneration induces type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression. Glia. 2019;67(7):1254&#x2013;1276. doi: 10.1002/glia.23592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23592</ArticleId><ArticleId IdType="pmc">PMC6520218</ArticleId><ArticleId IdType="pubmed">30680794</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559(7713):269&#x2013;273. doi: 10.1038/s41586-018-0287-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0287-8</ArticleId><ArticleId IdType="pubmed">29973723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M&#xfc;ller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad L, Zhang S-Y, Casanova J-L, Sancho-Shimizu V. Human TBK1: a gatekeeper of neuroinflammation. Trends Mol Med. 2016;22(6):511&#x2013;527. doi: 10.1016/j.molmed.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4890605</ArticleId><ArticleId IdType="pubmed">27211305</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain. 2017;10(1):5. doi: 10.1186/s13041-017-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Olschowka JA, O&#x2019;Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11(1):98. doi: 10.1186/1742-2094-11-98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-98</ArticleId><ArticleId IdType="pmc">PMC4060849</ArticleId><ArticleId IdType="pubmed">24889886</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Malaspina A, van Noort JM, Amor S. Non-neuronal cells in ALS: role of glial, immune cells and blood-CNS barriers. Brain Pathol. 2016;26(2):248&#x2013;257. doi: 10.1111/bpa.12352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12352</ArticleId><ArticleId IdType="pmc">PMC8029111</ArticleId><ArticleId IdType="pubmed">26780491</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D&#x2019;Ambrosi N (2017) The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci 9(242)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143(12):3526&#x2013;3539. doi: 10.1093/brain/awaa309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa309</ArticleId><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Lo Coco D, Veglianese P, Vallarola A, Giordana MT, Marcon G, et al (2017) Amyotrophic lateral sclerosis, a multisystem pathology: insights into the role of TNF&#x3b1;. Mediators Inflamm 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610855</ArticleId><ArticleId IdType="pubmed">29081600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci. 2001;187(1):27&#x2013;34. doi: 10.1016/S0022-510X(01)00514-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00514-7</ArticleId><ArticleId IdType="pubmed">11440741</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Ehrhart J, Sanberg PR, Borlongan CV. Potential role of humoral IL-6 cytokine in mediating pro-inflammatory endothelial cell response in amyotrophic lateral sclerosis. Int J Mol Sci. 2018;19(2):423. doi: 10.3390/ijms19020423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19020423</ArticleId><ArticleId IdType="pmc">PMC5855645</ArticleId><ArticleId IdType="pubmed">29385088</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, et al. TDP-43 activates microglia through NF-&#x3ba;B and NLRP3 inflammasome. Exp Neurol. 2015;273:24&#x2013;35. doi: 10.1016/j.expneurol.2015.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.019</ArticleId><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter M, Spiller KJ, Dominique MA, Xu H, Hunter FW, Fang TC, et al. Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. Acta Neuropathol Commun. 2021;9(1):140. doi: 10.1186/s40478-021-01239-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01239-x</ArticleId><ArticleId IdType="pmc">PMC8377972</ArticleId><ArticleId IdType="pubmed">34412701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, Huang C, Bi F, Wu Q, Huang B, Liu X, et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 2013;32(13):1917&#x2013;1926. doi: 10.1038/emboj.2013.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.122</ArticleId><ArticleId IdType="pmc">PMC3981181</ArticleId><ArticleId IdType="pubmed">23714777</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz SH, Pinto S, Sebasti&#xe3;o AM, Brites D (2021) Astrocytes in amyotrophic lateral sclerosis. Exon Publications:35&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pubmed">34473439</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigadski T, Le&#xdf;mann V. The physiology of regulated BDNF release. Cell Tissue Res. 2020;382(1):15&#x2013;45. doi: 10.1007/s00441-020-03253-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-020-03253-2</ArticleId><ArticleId IdType="pmc">PMC7529619</ArticleId><ArticleId IdType="pubmed">32944867</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Clin Exp Neuroimmunol. 2016;7(2):126&#x2013;138. doi: 10.1111/cen3.12309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen3.12309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi P, Rodriguez-Muela N, Klim JR, de Boer AS, Agrawal S, Sandoe J, et al. Reactive astrocytes promote ALS-like degeneration and intracellular protein aggregation in human motor neurons by disrupting autophagy through TGF-&#x3b2;1. Stem Cell Rep. 2017;9(2):667&#x2013;680. doi: 10.1016/j.stemcr.2017.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.06.008</ArticleId><ArticleId IdType="pmc">PMC5549875</ArticleId><ArticleId IdType="pubmed">28712846</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, et al. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015;11(4):592&#x2013;604. doi: 10.1016/j.celrep.2015.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P-S, Dhull DK, Nalini A, Vijayalakshmi K, Sathyaprabha TN, Alladi PA, et al. Astroglia acquires a toxic neuroinflammatory role in response to the cerebrospinal fluid from amyotrophic lateral sclerosis patients. J Neuroinflammation. 2016;13(1):212. doi: 10.1186/s12974-016-0698-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0698-0</ArticleId><ArticleId IdType="pmc">PMC5006495</ArticleId><ArticleId IdType="pubmed">27578023</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol. 2015;27(3):117&#x2013;129. doi: 10.1093/intimm/dxu099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu099</ArticleId><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottum PA, Arellano G, Reyes LI, Iruretagoyena M, Naves R. Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front Immunol. 2015;6:539. doi: 10.3389/fimmu.2015.00539.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00539</ArticleId><ArticleId IdType="pmc">PMC4626643</ArticleId><ArticleId IdType="pubmed">26579119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim H-J. Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp Neurobiol. 2015;24(1):1&#x2013;7. doi: 10.5607/en.2015.24.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.1.1</ArticleId><ArticleId IdType="pmc">PMC4363329</ArticleId><ArticleId IdType="pubmed">25792864</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell. 2011;147(3):498&#x2013;508. doi: 10.1016/j.cell.2011.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.10.011</ArticleId><ArticleId IdType="pmc">PMC3220614</ArticleId><ArticleId IdType="pubmed">22036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1(3):305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560466</ArticleId><ArticleId IdType="pubmed">23383400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Petri S, Kipiani K, Gardian G, Choi D-K, Chen J, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2006;26(9):2467&#x2013;2473. doi: 10.1523/JNEUROSCI.5253-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5253-05.2006</ArticleId><ArticleId IdType="pmc">PMC6793668</ArticleId><ArticleId IdType="pubmed">16510725</ArticleId></ArticleIdList></Reference><Reference><Citation>Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):393&#x2013;404. doi: 10.3109/17482960802709416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802709416</ArticleId><ArticleId IdType="pmc">PMC3820489</ArticleId><ArticleId IdType="pubmed">19922130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e100. doi: 10.1212/NXI.0000000000000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Woodruff TM. TDP-43 Puts the STING in ALS. Trends Neurosci. 2021;44(2):81&#x2013;82. doi: 10.1016/j.tins.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.12.001</ArticleId><ArticleId IdType="pubmed">33353765</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Liu D, Li Z, Bian J. Bioactive modulators targeting STING adaptor in cGAS-STING pathway. Drug Discovery Today. 2020;25(1):230&#x2013;237. doi: 10.1016/j.drudis.2019.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.11.007</ArticleId><ArticleId IdType="pubmed">31758915</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena SK (2016) Advances in molecular retrovirology: BoD&#x2013;Books on demand</Citation></Reference><Reference><Citation>Coffin JM (2018) Replication of retrovirus genomes. RNA Genetics: Volume II: Retroviruses, viroids, and RNA recombination</Citation></Reference><Reference><Citation>Isache C, Sands M, Guzman N, Figueroa D. HTLV-1 and HIV-1 co-infection: a case report and review of the literature. IDCases. 2016;4:53&#x2013;55. doi: 10.1016/j.idcr.2016.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2016.03.002</ArticleId><ArticleId IdType="pmc">PMC4840448</ArticleId><ArticleId IdType="pubmed">27144124</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifford RJ, Blomberg J, Coffin JM, Fan H, Heidmann T, Mayer J, et al. Nomenclature for endogenous retrovirus (ERV) loci. Retrovirology. 2018;15(1):59. doi: 10.1186/s12977-018-0442-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-018-0442-1</ArticleId><ArticleId IdType="pmc">PMC6114882</ArticleId><ArticleId IdType="pubmed">30153831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourque G, Burns KH, Gehring M, Gorbunova V, Seluanov A, Hammell M, et al. Ten things you should know about transposable elements. Genome Biol. 2018;19(1):199. doi: 10.1186/s13059-018-1577-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-018-1577-z</ArticleId><ArticleId IdType="pmc">PMC6240941</ArticleId><ArticleId IdType="pubmed">30454069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Pan J, Cong Y, Mao J. Transcriptional regulation of endogenous retroviruses and their misregulation in human diseases. Int J Mol Sci. 2022;23(17):10112. doi: 10.3390/ijms231710112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231710112</ArticleId><ArticleId IdType="pmc">PMC9456331</ArticleId><ArticleId IdType="pubmed">36077510</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee M-H, Henderson L, Tyagi R, Bachani M, Steiner J, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7(307):307ra153&#x2013;307ra153. doi: 10.1126/scitranslmed.aac8201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac8201</ArticleId><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl WE, Patel N, Halm K, Johnson WE. Tracking interspecies transmission and long-term evolution of an ancient retrovirus using the genomes of modern mammals. Elife. 2016;5:e12704. doi: 10.7554/eLife.12704.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.12704</ArticleId><ArticleId IdType="pmc">PMC4798954</ArticleId><ArticleId IdType="pubmed">26952212</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ry P, Nath A, Cr&#xe9;ange A, Dolei A, Marche P, Gold J, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med. 2018;24(4):379&#x2013;394. doi: 10.1016/j.molmed.2018.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.02.007</ArticleId><ArticleId IdType="pmc">PMC7185488</ArticleId><ArticleId IdType="pubmed">29551251</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishat S, Jessica F, Owen H, Seddon J, Simmons G, Speight N, et al (2020) Koala retrovirus viral load and disease burden in distinct northern and southern koala populations. Scientific Reports (Nature Publisher Group). 10(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6959342</ArticleId><ArticleId IdType="pubmed">31937823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al (2001) Initial sequencing and analysis of the human genome</Citation><ArticleIdList><ArticleId IdType="pubmed">11237011</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocking C, Kozak C. Endogenous retroviruses. Cell Mol Life Sci. 2008;65(21):3383&#x2013;3398. doi: 10.1007/s00018-008-8497-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-8497-0</ArticleId><ArticleId IdType="pmc">PMC4802364</ArticleId><ArticleId IdType="pubmed">18818872</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Akagi K, Hu Y, Trivett AL, Hlynialuk CJ, Swing DA, et al. Mouse endogenous retroviruses can trigger premature transcriptional termination at a distance. Genome Res. 2012;22(5):870&#x2013;884. doi: 10.1101/gr.130740.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.130740.111</ArticleId><ArticleId IdType="pmc">PMC3337433</ArticleId><ArticleId IdType="pubmed">22367191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz J. HERV-K HML-2 diversity among humans. Proc Natl Acad Sci. 2016;113(16):4240. doi: 10.1073/pnas.1603569113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603569113</ArticleId><ArticleId IdType="pmc">PMC4843480</ArticleId><ArticleId IdType="pubmed">27071126</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntsova M, Garazha A, Ivanova A, Kaminsky D, Zhavoronkov A, Buzdin A. Molecular functions of human endogenous retroviruses in health and disease. Cell Mol Life Sci. 2015;72(19):3653&#x2013;3675. doi: 10.1007/s00018-015-1947-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-1947-6</ArticleId><ArticleId IdType="pubmed">26082181</ArticleId></ArticleIdList></Reference><Reference><Citation>Nex&#xf8; BA, Villesen P, Nissen KK, Lindegaard HM, Rossing P, Petersen T, et al. Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. Immunol Res. 2016;64(1):55&#x2013;63. doi: 10.1007/s12026-015-8671-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-015-8671-z</ArticleId><ArticleId IdType="pmc">PMC4726719</ArticleId><ArticleId IdType="pubmed">26091722</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville RN, Nath A (2014) Chapter 22 - Human endogenous retroviruses and the nervous system. In: Tselis AC, Booss J (eds) Handbook of clinical neurology. 123: Elsevier; p. 465&#x2013;85</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4903019</ArticleId><ArticleId IdType="pubmed">25015500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi S, Lee X, Li X-p, Veldman GM, Finnerty H, Racie L, et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature. 2000;403(6771):785&#x2013;9. doi: 10.1038/35001608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35001608</ArticleId><ArticleId IdType="pubmed">10693809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuong EB. The placenta goes viral: retroviruses control gene expression in pregnancy. PLoS Biol. 2018;16(10):e3000028-e. doi: 10.1371/journal.pbio.3000028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000028</ArticleId><ArticleId IdType="pmc">PMC6177113</ArticleId><ArticleId IdType="pubmed">30300353</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao S, Wang F, Chen H, Jiang S-W. Inducible knockout of syncytin-A gene leads to an extensive placental vasculature deficiency, implications for preeclampsia. Clin Chim Acta. 2017;474:137&#x2013;146. doi: 10.1016/j.cca.2017.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.09.012</ArticleId><ArticleId IdType="pubmed">28935154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolei A. The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis. Mult Scler J. 2018;24(1):42&#x2013;47. doi: 10.1177/1352458517737370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517737370</ArticleId><ArticleId IdType="pubmed">29307292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer D, Gruchot J, Weyers V, Oldemeier L, Goettle P, Healy L, et al (eds) (2018) Microglial-dependent neurodegeneration in multiple sclerosis is fueled by HERV-W envelope protein. MULTIPLE SCLEROSIS JOURNAL; SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND</Citation></Reference><Reference><Citation>Ruprecht K, Mayer J (2019) On the origin of a pathogenic HERV-W envelope protein present in multiple sclerosis lesions. Proc Natl Acad Sci U.S.A. 201911703</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778242</ArticleId><ArticleId IdType="pubmed">31455746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen HB, Geny C, Deforges L, Perron H, Tourtelotte W, Heltberg A, et al. Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. Mult Scler J. 1995;1(2):82&#x2013;87. doi: 10.1177/135245859500100205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859500100205</ArticleId><ArticleId IdType="pubmed">9345457</ArticleId></ArticleIdList></Reference><Reference><Citation>Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, et al. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler J. 2012;18(12):1721&#x2013;1736. doi: 10.1177/1352458512441381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458512441381</ArticleId><ArticleId IdType="pmc">PMC3573672</ArticleId><ArticleId IdType="pubmed">22457345</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-P&#xe9;rez S, Dom&#xed;nguez-Mozo MI, Garc&#xed;a-Mart&#xed;nez M&#xc1;, Ballester-Gonz&#xe1;lez R, Nieto-Ga&#xf1;&#xe1;n I, Arroyo R, et al. Epstein-Barr virus load correlates with multiple sclerosis-associated retrovirus envelope expression. Biomedicines. 2022;10(2):387. doi: 10.3390/biomedicines10020387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10020387</ArticleId><ArticleId IdType="pmc">PMC8962350</ArticleId><ArticleId IdType="pubmed">35203596</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51&#x2013;64. doi: 10.1038/s41579-022-00770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00770-5</ArticleId><ArticleId IdType="pmc">PMC9362539</ArticleId><ArticleId IdType="pubmed">35931816</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandi N, Tramontano E (2018) HERV envelope proteins: physiological role and pathogenic potential in cancer and autoimmunity. Front Microbiol 9(462)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861771</ArticleId><ArticleId IdType="pubmed">29593697</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen T. HERVs in neuropathogenesis. J Neuroimmune Pharmacol. 2010;5(3):326&#x2013;335. doi: 10.1007/s11481-010-9214-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-010-9214-y</ArticleId><ArticleId IdType="pubmed">20422298</ArticleId></ArticleIdList></Reference><Reference><Citation>Rycaj K, Plummer JB, Yin B, Li M, Garza J, Radvanyi L, et al. Cytotoxicity of human endogenous retrovirus K&#x2013;specific T cells toward autologous ovarian cancer cells. Clin Cancer Res. 2015;21(2):471&#x2013;483. doi: 10.1158/1078-0432.CCR-14-0388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0388</ArticleId><ArticleId IdType="pubmed">25370465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang-Johanning F, Frost AR, Jian B, Epp L, Lu DW, Johanning GL. Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene. 2003;22(10):1528&#x2013;1535. doi: 10.1038/sj.onc.1206241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1206241</ArticleId><ArticleId IdType="pubmed">12629516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mameli G, Erre GL, Caggiu E, Mura S, Cossu D, Bo M, et al. Identification of a HERV-K env surface peptide highly recognized in Rheumatoid Arthritis (RA) patients: a cross-sectional case&#x2013;control study. Clin Exp Immunol. 2017;189(1):127&#x2013;131. doi: 10.1111/cei.12964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12964</ArticleId><ArticleId IdType="pmc">PMC5461087</ArticleId><ArticleId IdType="pubmed">28324619</ArticleId></ArticleIdList></Reference><Reference><Citation>Leboyer M, Tamouza R, Charron D, Faucard R, Perron H. Human endogenous retrovirus type W (HERV-W) in schizophrenia: a new avenue of research at the gene&#x2013;environment interface. World J Biol Psychiatry. 2013;14(2):80&#x2013;90. doi: 10.3109/15622975.2010.601760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/15622975.2010.601760</ArticleId><ArticleId IdType="pubmed">21936762</ArticleId></ArticleIdList></Reference><Reference><Citation>Slokar G, Hasler G. Human endogenous retroviruses as pathogenic factors in the development of schizophrenia. Front Psych. 2016;6:183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707225</ArticleId><ArticleId IdType="pubmed">26793126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer K (2019) Human endogenous retroviruses and disease</Citation></Reference><Reference><Citation>Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology. 2011;8(1):90. doi: 10.1186/1742-4690-8-90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-8-90</ArticleId><ArticleId IdType="pmc">PMC3228705</ArticleId><ArticleId IdType="pubmed">22067224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease. Front Oncol. 2013;3:246. doi: 10.3389/fonc.2013.00246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2013.00246</ArticleId><ArticleId IdType="pmc">PMC3778440</ArticleId><ArticleId IdType="pubmed">24066280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SH (2015) Reverse transcription of retroviruses and LTR retrotransposons. Mobile DNA III: American Society of Microbiology; p. 1051-77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6775776</ArticleId><ArticleId IdType="pubmed">26104704</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifford R, Tristem M (2003) The evolution, distribution and diversity of endogenous retroviruses. 291&#x2013;315 p</Citation><ArticleIdList><ArticleId IdType="pubmed">12876457</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SM, Sapir T, Park S-S, Rual J-F, Contreras-Galindo R, Reiner O, et al. The HERV-K accessory protein Np9 controls viability and migration of teratocarcinoma cells. PLoS One. 2019;14(2):e0212970. doi: 10.1371/journal.pone.0212970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212970</ArticleId><ArticleId IdType="pmc">PMC6394991</ArticleId><ArticleId IdType="pubmed">30818388</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt K, Heyne K, Roemer K, Meese E, Mayer J. HERV-K(HML-2) rec and np9 transcripts not restricted to disease but present in many normal human tissues. Mob DNA. 2015;6(1):4. doi: 10.1186/s13100-015-0035-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13100-015-0035-7</ArticleId><ArticleId IdType="pmc">PMC4351823</ArticleId><ArticleId IdType="pubmed">25750667</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewannieux M, Blaise S, Heidmann T. Identification of a functional envelope protein from the HERV-K family of human endogenous retroviruses. J Virol. 2005;79(24):15573&#x2013;15577. doi: 10.1128/JVI.79.24.15573-15577.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.24.15573-15577.2005</ArticleId><ArticleId IdType="pmc">PMC1315997</ArticleId><ArticleId IdType="pubmed">16306628</ArticleId></ArticleIdList></Reference><Reference><Citation>Boller K, Sch&#xf6;nfeld K, Lischer S, Fischer N, Hoffmann A, Kurth R, et al. Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J Gen Virol. 2008;89(2):567&#x2013;572. doi: 10.1099/vir.0.83534-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83534-0</ArticleId><ArticleId IdType="pubmed">18198388</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin W, Lee J, Son S-Y, Ahn K, Kim H-S, Han K. Human-specific HERV-K insertion causes genomic variations in the human genome. PLoS One. 2013;8(4):e60605. doi: 10.1371/journal.pone.0060605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060605</ArticleId><ArticleId IdType="pmc">PMC3625200</ArticleId><ArticleId IdType="pubmed">23593260</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner G, Barbulescu M, Su M, Jensen-Seaman MI, Kidd KK, Lenz J. Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr Biol. 2001;11(19):1531&#x2013;1535. doi: 10.1016/S0960-9822(01)00455-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(01)00455-9</ArticleId><ArticleId IdType="pubmed">11591322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildschutte JH, Williams ZH, Montesion M, Subramanian RP, Kidd JM, Coffin JM. Discovery of unfixed endogenous retrovirus insertions in diverse human populations. Proc Natl Acad Sci. 2016;113(16):E2326&#x2013;E2334. doi: 10.1073/pnas.1602336113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1602336113</ArticleId><ArticleId IdType="pmc">PMC4843416</ArticleId><ArticleId IdType="pubmed">27001843</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola MV, Frazier M, White L, Brody J, Spiegelman S. RNA-instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients. J Exp Med. 1975;142(2):483&#x2013;494. doi: 10.1084/jem.142.2.483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.142.2.483</ArticleId><ArticleId IdType="pmc">PMC2189894</ArticleId><ArticleId IdType="pubmed">49390</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews W, Tuke P, Al-Chalabi A, Gaudin P, Ijaz S, Parton M, et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol. 2000;61(4):527&#x2013;532. doi: 10.1002/1096-9071(200008)61:4&lt;527::AID-JMV17&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1096-9071(200008)61:4&lt;527::AID-JMV17&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">10897073</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele A, Al-Chalabi A, Ferrante K, Cudkowicz M, Brown R, Garson J. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. 2005;64(3):454&#x2013;458. doi: 10.1212/01.WNL.0000150899.76130.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000150899.76130.71</ArticleId><ArticleId IdType="pubmed">15699374</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick A, Brown R, Cudkowicz M, Al-Chalabi A, Garson J. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008;70(4):278&#x2013;283. doi: 10.1212/01.wnl.0000297552.13219.b4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000297552.13219.b4</ArticleId><ArticleId IdType="pubmed">18209202</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. 2013;99(2):180&#x2013;187. doi: 10.1016/j.antiviral.2013.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.05.006</ArticleId><ArticleId IdType="pmc">PMC3723705</ArticleId><ArticleId IdType="pubmed">23707220</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology. 2001;57(6):995&#x2013;1001. doi: 10.1212/WNL.57.6.995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.6.995</ArticleId><ArticleId IdType="pubmed">11571323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen LN, Tyagi R, Li W, Alfahad T, Smith B, Wright M, et al. HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology. 2016;87(17):1756&#x2013;1762. doi: 10.1212/WNL.0000000000003258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003258</ArticleId><ArticleId IdType="pmc">PMC5089528</ArticleId><ArticleId IdType="pubmed">27664983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadlock K, Miller R, Jin X, Yu S, Reis J, Mass J, et al (eds) (2004) Elevated rates of antibody reactivity to HML-2/HERV-K but not other endogenous retroviruses in ALS. Neurology; LIPPINCOTT WILLIAMS &amp; WILKINS 530 WALNUT ST, PHILADELPHIA, PA 19106&#x2013;3621 USA</Citation></Reference><Reference><Citation>Garcia-Montojo M, Simula ER, Fathi S, McMahan C, Ghosal A, Berry JD, et al. Antibody response to HML-2 may be protective in amyotrophic lateral sclerosis. Ann Neurol. 2022;92(5):782&#x2013;792. doi: 10.1002/ana.26466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26466</ArticleId><ArticleId IdType="pmc">PMC9805205</ArticleId><ArticleId IdType="pubmed">36053951</ArticleId></ArticleIdList></Reference><Reference><Citation>Manghera M, Ferguson-Parry J, Douville RN. TDP-43 regulates endogenous retrovirus-K viral protein accumulation. Neurobiol Dis. 2016;94:226&#x2013;236. doi: 10.1016/j.nbd.2016.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.06.017</ArticleId><ArticleId IdType="pubmed">27370226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y-H, Dubnau J (2022) Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback to drive the intercellular spread of neurodegeneration. bioRxiv. 2022.07. 20.500816</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9944888</ArticleId><ArticleId IdType="pubmed">36810738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibba G, Piu C, Uleri E, Serra C, Dolei A. Disruption by SaCas9 endonuclease of HERV-Kenv, a retroviral gene with oncogenic and neuropathogenic potential, inhibits molecules involved in cancer and amyotrophic lateral sclerosis. Viruses. 2018;10(8):412. doi: 10.3390/v10080412.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10080412</ArticleId><ArticleId IdType="pmc">PMC6115762</ArticleId><ArticleId IdType="pubmed">30087231</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolei A, Ibba G, Piu C, Serra C. Expression of HERV genes as possible biomarker and target in neurodegenerative diseases. Int J Mol Sci. 2019;20(15):3706. doi: 10.3390/ijms20153706.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20153706</ArticleId><ArticleId IdType="pmc">PMC6696274</ArticleId><ArticleId IdType="pubmed">31362360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y-H, Dubnau J. Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of drosophila neurodegeneration. Nat Commun. 2023;14(1):966. doi: 10.1038/s41467-023-36649-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36649-z</ArticleId><ArticleId IdType="pmc">PMC9944888</ArticleId><ArticleId IdType="pubmed">36810738</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Manghera M, Douville RN. Endogenous retrovirus-K promoter: a landing strip for inflammatory transcription factors? Retrovirology. 2013;10(1):1&#x2013;11. doi: 10.1186/1742-4690-10-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-10-16</ArticleId><ArticleId IdType="pmc">PMC3598470</ArticleId><ArticleId IdType="pubmed">23394165</ArticleId></ArticleIdList></Reference><Reference><Citation>Manghera M, Ferguson J, Douville R. ERVK polyprotein processing and reverse transcriptase expression in human cell line models of neurological disease. Viruses. 2015;7(1):320&#x2013;332. doi: 10.3390/v7010320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7010320</ArticleId><ArticleId IdType="pmc">PMC4306841</ArticleId><ArticleId IdType="pubmed">25609305</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Curzio D, Gurm M, Turnbull M, Nadeau M-J, Meek B, Rempel JD, et al. Pro-inflammatory signaling upregulates a neurotoxic conotoxin-like protein encrypted within human endogenous retrovirus-K. Cells. 2020;9(7):1584. doi: 10.3390/cells9071584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071584</ArticleId><ArticleId IdType="pmc">PMC7407490</ArticleId><ArticleId IdType="pubmed">32629888</ArticleId></ArticleIdList></Reference><Reference><Citation>Arru G, Galleri G, Deiana GA, Zarbo IR, Sechi E, Bo M, et al. HERV-K modulates the immune response in ALS patients. Microorganisms. 2021;9(8):1784. doi: 10.3390/microorganisms9081784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9081784</ArticleId><ArticleId IdType="pmc">PMC8399181</ArticleId><ArticleId IdType="pubmed">34442863</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y-H, Dubnau J. The gypsy endogenous retrovirus drives non-cell-autonomous propagation in a drosophila TDP-43 model of neurodegeneration. Curr Biol. 2019;29(19):3135&#x2013;52.e4. doi: 10.1016/j.cub.2019.07.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2019.07.071</ArticleId><ArticleId IdType="pmc">PMC6783360</ArticleId><ArticleId IdType="pubmed">31495585</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Endogenous retroviruses in ALS: a reawakening? Sci Transl Med. 2015;7(307):307fs40&#x2013;fs40. doi: 10.1126/scitranslmed.aad3533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad3533</ArticleId><ArticleId IdType="pubmed">26424566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi R, Li W, Parades D, Bianchet MA, Nath A. Inhibition of human endogenous retrovirus-K by antiretroviral drugs. Retrovirology. 2017;14(1):21. doi: 10.1186/s12977-017-0347-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-017-0347-4</ArticleId><ArticleId IdType="pmc">PMC5361811</ArticleId><ArticleId IdType="pubmed">28330477</ArticleId></ArticleIdList></Reference><Reference><Citation>Scelsa S, MacGowan D, Mitsumoto H, Imperato T, LeValley A, Liu M, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology. 2005;64(7):1298&#x2013;1300. doi: 10.1212/01.WNL.0000156913.24701.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000156913.24701.72</ArticleId><ArticleId IdType="pubmed">15824372</ArticleId></ArticleIdList></Reference><Reference><Citation>Westarp ME, Bartmann P, R&#xf6;ssler J, Geiger E, Westphal KP, Schreiber H, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. NeuroReport. 1993;4(6):819&#x2013;822. doi: 10.1097/00001756-199306000-00056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199306000-00056</ArticleId><ArticleId IdType="pubmed">8394159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubernick SI, F&#xe9;lix N, Lee D, Xu JJ, Hamad B (2016) The HIV therapy market. Nature Publishing Group</Citation><ArticleIdList><ArticleId IdType="pubmed">27312723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ene L, Duiculescu D, Ruta S. How much do antiretroviral drugs penetrate into the central nervous system? J Med Life. 2011;4(4):432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227164</ArticleId><ArticleId IdType="pubmed">22514580</ArticleId></ArticleIdList></Reference><Reference><Citation>Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of Dolutegravir in cerebrospinal fluid in HIV-1&#x2013;infected, antiretroviral therapy&#x2013;naive subjects. Clin Infect Dis. 2014;59(7):1032&#x2013;1037. doi: 10.1093/cid/ciu477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu477</ArticleId><ArticleId IdType="pmc">PMC4166983</ArticleId><ArticleId IdType="pubmed">24944232</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Liu Z, Wu Z, Ren J, Fan Y, Sun L, et al (2023) Resurrection of endogenous retroviruses during aging reinforces senescence. Cell</Citation><ArticleIdList><ArticleId IdType="pubmed">36610399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93&#x2013;100. doi: 10.1007/s11904-017-0356-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-017-0356-x</ArticleId><ArticleId IdType="pmc">PMC5514315</ArticleId><ArticleId IdType="pubmed">28434169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, et al. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis. 2014;14(1):1&#x2013;9. doi: 10.1186/1471-2334-14-122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-122</ArticleId><ArticleId IdType="pmc">PMC3945800</ArticleId><ArticleId IdType="pubmed">24589015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RP, et al (2019) Safety and tolerability of triumeq in amyotrophic lateral sclerosis: the lighthouse trial</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, Fathi S, Norato G, Smith B, Rowe D, Kiernan M, et al. Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy. J Neurol Sci. 2021;423:117358. doi: 10.1016/j.jns.2021.117358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117358</ArticleId><ArticleId IdType="pmc">PMC8009857</ArticleId><ArticleId IdType="pubmed">33653604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, et al. A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Mult Scler Relat Disord. 2018;24:123&#x2013;128. doi: 10.1016/j.msard.2018.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2018.06.002</ArticleId><ArticleId IdType="pubmed">29990894</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Jin Y, Prazak L, Hammell M, Dubnau J. Transposable elements in TDP-43-mediated neurodegenerative disorders. PLoS One. 2012;7(9):e44099. doi: 10.1371/journal.pone.0044099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044099</ArticleId><ArticleId IdType="pmc">PMC3434193</ArticleId><ArticleId IdType="pubmed">22957047</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao W-W, Morrill K, et al. Retrotransposon activation contributes to neurodegeneration in a drosophila TDP-43 model of ALS. PLoS Genet. 2017;13(3):e1006635. doi: 10.1371/journal.pgen.1006635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006635</ArticleId><ArticleId IdType="pmc">PMC5354250</ArticleId><ArticleId IdType="pubmed">28301478</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares P, Silva C, Chavarria D, Silva FS, Oliveira PJ, Borges F (2022) Drug discovery and amyotrophic lateral sclerosis: emerging challenges and therapeutic opportunities. Ageing Res Rev 101790</Citation><ArticleIdList><ArticleId IdType="pubmed">36402404</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating SS, San Gil R, Swanson MEV, Scotter EL, Walker AK. TDP-43 pathology: from noxious assembly to therapeutic removal. Prog Neurobiol. 2022;211:102229. doi: 10.1016/j.pneurobio.2022.102229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2022.102229</ArticleId><ArticleId IdType="pubmed">35101542</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>